All Stories

  1. The spectrum of psychosis in people with neurological disease
  2. Association of a five-metabolite and early-symptom profile with Parkinson’s disease and its clinical progression
  3. TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations
  4. An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson’s disease
  5. Incidence of Sporadic Creutzfeldt-Jakob Disease in the Emergency Department
  6. Unraveling the Link between Sleep Disturbances and Parkinson’s Disease: A Narrative Review
  7. Developing personalized treatment strategies for Parkinson’s disease based on disease subtypes
  8. EPIDEMIOLOGY OF LEVODOPA-INDUCED DYSKINESIA: PREVALENCE AND ASSOCIATED CLINICAL FACTORS IN LATIN AMERICA
  9. Genotype-phenotype association study conducted on LARGE-PD reveals novel loci associated with Parkinson’s Disease
  10. Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
  11. Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores
  12. Condiciones de igualdad entre médicas y médicos en 2021 en el Instituto Nacional de Neurología y Neurocirugía
  13. Influencia del sexo y del estado funcional en el bienestar emocional en la enfermedad de Parkinson: conocimientos de un estudio transversal
  14. Sex differences in the diagnosis latency of Parkinson's disease in Latin America
  15. The LRRK2 p.L1795F variant causes Parkinson’s disease in the European population
  16. Establishing a MoCA cut-off point for cognitive impairment detection in Mexican people living with Parkinson's disease: A comprehensive assessment (level II) approach
  17. Revisión exploratoria sobre los tratamientos experimentales para la enfermedad de Parkinson: terapias de precisión y de amplio espectro
  18. Factores de riesgo para el desarrollo de trastornos del control de impulsos en sujetos mexicanos con enfermedad de Parkinson
  19. Association between alterations in sleep spindles and cognitive decline in persons with Parkinson’s disease
  20. Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study
  21. Weak association between total alpha‐synuclein reflex tear levels and non‐motor symptoms burden in Parkinson's disease
  22. Movement disorders in opioid users observed in the social networks: a systematic review
  23. Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
  24. A Characterization of Central Auditory Processing in Parkinson’s Disease
  25. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
  26. Building national patient registries in Mexico: insights from the MexOMICS Consortium
  27. Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome
  28. The Importance of Standardized Assessment
  29. Levodopa Versus Levodopa Sparing in Early Parkinson‘s Disease: Can we Meet Halfway?
  30. Electrocardiographic approach strategies in patients with Parkinson disease treated with deep brain stimulation
  31. Establishment of induced pluripotent stem cell lines derived from Parkinson’s disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1
  32. Parkinson's disease-associated pain in a Mexican Institute
  33. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose‐Driven Approach
  34. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus
  35. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
  36. Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease
  37. Pro-inflammatory cytokines levels in tears and dry eye disease in Parkinson’s disease
  38. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study
  39. Building National Patient Registries in Mexico: Insights from the MexOMICS Consortium.
  40. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)
  41. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
  42. Clinical and genetic insights of Parkinson’s Disease in a Mexican cohort: highlighting Latino’s diversity
  43. Neuropsychiatric and young-onset as clinical determinants for a delayed HuntingtonÓ?s disease diagnosis
  44. Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset
  45. Determinants and impact of alexithymia on quality of life in Parkinson's disease
  46. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease?
  47. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
  48. Association between cardiometabolic comorbidities and Parkinson’s disease in a Mexican population
  49. Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic
  50. Documento de postura: la afectación de personal médico y de la salud en la pandemia de SARS-CoV-2
  51. Expanded and Independent Spanish Validation of the MDS‐Non Motor Rating Scale
  52. Experience with Creutzfeldt-Jakob disease in a single referral center in Mexico. Case series
  53. Attentional impairment in Parkinson’s disease is modulated by side of onset: Neurophysiological evidence
  54. Association between dopaminergic-induced complications and life satisfaction in ParkinsonÓ?s disease
  55. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson’s disease
  56. COVID-19 and Integrated Multidisciplinary Care Model in Parkinson’s Disease: Literature Review & Future Perspectives
  57. Pitfalls and caveats in the diagnostic pathway of people with ParkinsonÓ?s disease
  58. Experiencia con la enfermedad de Creutzfeldt-Jakob de un único centro de referencia en México. Análisis de una serie de casos
  59. Fellowship training: a collateral damage of Covid-19 pandemic
  60. Living with chronic illness scale in Parkinson's disease: Longitudinal metric properties and meaningful change
  61. Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
  62. Satisfaction With Telemedicine Consultation as Follow-Up Visit in Patients with Parkinsonism and Essential Tremor in during the Covid-19 Pandemic
  63. Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
  64. Spotlight on non-motor symptoms and Covid-19
  65. The neuropsychiatry of Parkinson's disease: advances and challenges
  66. Editorial: Managing Parkinson's Disease With a Multidisciplinary Perspective
  67. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease
  68. Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana
  69. Self-reported olfactory dysfunction in Mexican healthcare workers during the first six months of the COVID-19 pandemic: A nationwide online survey study
  70. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  71. Pro- and anti-inflammatory response in neurological disorders associated to anti-glutamate decarboxylase antibodies
  72. Editorial: Measurement Tools for Clinical Assessment, Characterization and Neurorehabilitation of Parkinson's Disease
  73. Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life
  74. Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
  75. Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations
  76. Worldwide barriers to genetic testing for movement disorders
  77. Frontal functional connectivity and disease duration interactively predict cognitive decline in Parkinson's disease
  78. Incidencia y distribución geográfica de la enfermedad de Parkinson en México
  79. Malnutrition and Associated Motor and Non-motor Factors in People with Parkinson's Disease
  80. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease
  81. Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations
  82. First report of pathogenic SGCE variants in Mexican patients with myoclonus dystonia: A five-year follow-up study
  83. Manifestaciones neurológicas en la enfermedad del coronavirus 2019
  84. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  85. Editorial: Patient Empowerment and Person-Centered Care in Movement Disorders
  86. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  87. Teaching neurology to “Millennials:” Basic concepts and recommendations
  88. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  89. Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson’s disease
  90. Review of Hereditary and Acquired Rare Choreas
  91. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  92. Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al.
  93. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  94. Gait in Parkinson’s Disease
  95. Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
  96. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly
  97. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  98. Análisis de subtipos motores en la enfermedad de Parkinson: Registro Mexicano de Enfermedad de Parkinson (ReMePARK)
  99. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations
  100. Influencing factors when living with Parkinson’s disease: A cross‐sectional study
  101. Air Pollution, Multiple Sclerosis and its Relevance to Mexico City
  102. Terapias de infusión en la enfermedad de Parkinson avanzada
  103. The Parkinson's Disease Sleep Scale–2 (PDSS‐2): Validation of the Spanish Version and Its Relationship With a Roommate‐Based Version
  104. Brief historical review of Parkinson’s disease at 200 years of its description
  105. Low diagnostic accuracy of fragile X tremor/ataxia syndrome diagnostic criteria in late onset ataxia
  106. Diseño y evaluación curricular de un curso de posgrado de alta especialidad en medicina
  107. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  108. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  109. Huntington's disease-like disorders in Latin America and the Caribbean
  110. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  111. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  112. Etiología, fenomenología, clasificación y tratamiento de la distonía
  113. Indirect Costs of Parkinson Disease Health Care in the National Institute of Neurology and Neurosurgery in the Mexico City
  114. Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism
  115. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  116. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  117. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  118. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  119. Treatable inherited rare movement disorders
  120. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
  121. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative a...
  122. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  123. Spotlight on olfactory dysfunction in Parkinson's disease
  124. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  125. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  126. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  127. Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings
  128. Living with chronic illness scale: international validation of a new self-report measure in Parkinson’s disease
  129. Analysis of four scales for global severity evaluation in Parkinson’s disease
  130. Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population
  131. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  132. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  133. Parkinson disease and progressive supranuclear palsy: protein expression in skin
  134. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  135. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  136. Theory of the mind in subjects with Parkinson's disease: A case-control study
  137. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  138. Frecuencia de polimorfismos de nucleótido único y haplotipos de alfa-sinucleína asociados con la enfermedad de Parkinson esporádica en población mexicana
  139. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  140. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  141. The P3a wave: A reliable neurophysiological measure of Parkinson’s disease duration and severity
  142. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  143. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  144. Electroconvulsive therapy in Parkinson´s disease
  145. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  146. Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers
  147. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  148. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
  149. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  150. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  151. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  152. Cardiovascular variability in Mexican patients with Parkinson's disease
  153. Impulse control and related disorders in Mexican Parkinson's disease patients
  154. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  155. Simultaneous Presentation of Ocular Flutter in Two Sisters
  156. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  157. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  158. Vas Eq-5d Utility Index In Parkinson’s Disease
  159. Direct Medical Costs Related To Parkinson’s Disease
  160. A Relationship Between Eq-5d Health State Classifications And Eq Vas Scores In Parkinson’s Disease
  161. A reappraisal of the ten steps test for identifying atypical parkinsonism
  162. Initial circulatory response to active standing in Parkinson's disease without typical orthostatic hypotension
  163. Genetic mutations in early-onset Parkinson's disease Mexican patients: Molecular testing implications
  164. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients
  165. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  166. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  167. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  168. Cervical Dystonia
  169. Apathy and associated factors in Mexican patients with Parkinson’s disease
  170. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease
  171. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale
  172. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  173. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  174. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  175. Overweight is more prevalent in patients with Parkinson's disease
  176. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  177. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
  178. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  179. Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
  180. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease
  181. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  182. A prospective series of patients with hyperglycaemia-associated movement disorders
  183. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  184. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  185. Involuntary attention impairment in early Parkinson's disease: An event-related potential study
  186. Sympathetic Cooling in an Optically Trapped Mixture of Alkali and Spin-Singlet Atoms
  187. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  188. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  189. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease
  190. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  191. Association of a history of varicella virus infection with multiple sclerosis
  192. SEQUENTIAL STAR FORMATION IN A COMETARY GLOBULE (BRC37) OF IC1396
  193. Uso clínico de autoanticuerpos en neurología
  194. Quality of life in patients with Parkinson's disease